Thijs van Haaps/LinkedIn
Oct 29, 2025, 07:38
Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
RPTH Journal shared a post on LinkedIn:
“New in RPTH!
Thijs van Haaps and team show that Andexanet alfa may go beyond apixaban and rivaroxaban—showing reversal potential for enoxaparin. In both healthy volunteers and bleeding patients, anti-Xa activity fell rapidly and 88% achieved good hemostasis.”
Title: Andexanet Alfa for the Reversal of the Low-Molecular-Weight Heparin Enoxaparin
Authors: Thijs F. van Haaps, Alexander P. Benz, Lizhen Xu, Saskia Middeldorp, John W. Eikelboom, Truman J. Milling, Jr., Mark Crowther, Lisa Holer, Stephan Nolan, Per Ladenvall, Genmin Lu, Michiel Coppens
Read more here.
Stay updated with Hemostasis Today.
-
Dec 14, 2025, 16:06Dr Abdul Mannan: What’s Your Approach to Diagnosing Iron Deficiency in Tricky Cases?
-
Dec 14, 2025, 16:05Mark Young – 46 Shadow Gates: How Your Chromosomes Archive Ancestral Memory
-
Dec 14, 2025, 16:04NNHF Unveiled at ASH2025: a Bold New Chapter was Marked – Expanding Beyond Haemophilia Care to Include SCD and Thalassemia
-
Dec 14, 2025, 15:46Heghine Khachatryan about PVCS as Cause of Chronic Pelvic Pain and Lower-Extremity/Pelvic Varices in Women
-
Dec 14, 2025, 15:42Gianluca Franceschini – Prevention is the Future: Investing Today to Save Lives Tomorrow
-
Dec 14, 2025, 13:55Indunil Karunarathna: Anticoagulation Therapy in Atrial Fibrillation Risks and Benefits
-
Dec 14, 2025, 12:56Mentored by Riten Kumar, Sriveda Boyalakuntla Presents Key Research on Infection-Associated Thrombosis at ASH25
-
Dec 14, 2025, 12:54Paul Roscoe: Deeply Proud of the Mend Care Team in This Intervention
-
Dec 13, 2025, 20:23Wolfgang Miesbach: From Daily Pills to Remission after Short‑Course Therapy in ITP